Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 RESTORATiVE303 trial of VE303 to prevent recurrent Clostridioides difficile infection
MOH_2024-08-01_013427Phase 3Not yet recruiting
- Sponsor
- Vedanta Biosciences
- Start
- Apr 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VE303 in Clostridioides difficile colitis (CDI) and Clostridioides difficile infection recurrence (rCDI) (4 arms), sponsored by Vedanta Biosciences. Primary endpoints: Recurrent Clostridioides difficile infection at Week 8 and Safety. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
VE303
03
Conditions
Clostridioides difficile colitis (CDI)Clostridioides difficile infection recurrence (rCDI)
Beyond the preview
Go deeper on MOH_2024-08-01_013427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-01_013427.